tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome cMichael C. Wei, Stanley J. Korsmeyer|Genes & Development|2000Cited by 1.3k
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Matthew J. Matasar et al.|The Lancet Oncology|2022Cited by 429